欢迎来到天天文库
浏览记录
ID:32352120
大小:4.32 MB
页数:27页
时间:2019-02-03
《218例小细胞肺癌患者预后多因素分析》由会员上传分享,免费在线阅读,更多相关内容在学术论文-天天文库。
1、大连医科大学硕士学位论文Analysisof218casesofmultiplefactorsandprognosisofsmallcelllungcancerpatientsMasterdegreecandidate:KouJinSupervisor:ProfessorSunTaoVice—supervisor:ProfessorJingMingxiMajor:OncologyAbstractobjeetive:smallcelllungcancermalignantdegreeishi曲,stronginvas
2、ion,prognosisispoor,inrecentyearsinthetreatmensurfacedidnotprogressofamazing,thispaperretrospectivelyanalysistheinfluenceofsmallcellprognosticfactorsinlungCanCer.Methods:111etumorhospitalofLiaoningProvincein2003Januaryto2011Decemberweretreatedbyclinicaldataof2
3、18patients、加tllsmallcelllungcancertissuehistologicallyorcytologicallydiagnosed,respectivelyonthegender,age,smokinghistory,KPSscore,weightloss,staging,treatmentmodalities,first—linechemotherapycycles,andeffectofprimarytreatment,laboratoryindexprojectofunivariat
4、eandmultivariateanalysis.SurvivalWasanalyzedusingtheKaplan-Meiermethodtocalculatethesurvivalrateandtomakethesurvivalcurve.UnivariateanalysisWasperformedbyLog—ranktest,andthesinglefactormeaningfulthroughtheCoxriskmodelselectionaffectstheprognosisfactors,P5、adsignificantdifferenceResults:Inthisstudy,allofthe218patients,1,2,3yearsurvivalrateswere61.5%,22.9%,11.9%,themediansurvivaltimeWas14.5months,152casesofpatients、Ⅳitlllimitedstage,66casesofpatients谢t11extensivestage.Inlimitedstage,1,2,3yearsurvivalrateswere70.46、%,27%,14.5%,,themediansurvivaltimeWas16.8months,inextensivestage,1,23yearsurvivalrateswere40.9%,13.6%,6.1%,themediansurvivaltimeWas8.8months,P<0.001,therearesignificantdifferences.KPSscore≥80patientsfor1year,2year,3yearsurvivalrateswere66.9%,27.5%,12.5%,KPS<807、patientsforlyear,2year,3yearsurvivalrateswere46.6%,10.3%,10.3%,P8、therearesignificant3大连医科大学硕士学位论文differences.First-linechemotherapycyclecount<4cycleswerel,2,3yearsurvivalrateswere41.1%,16.1%,7.1%,first—linechemotherapycyclecount≥4cycleswere1,2,3
5、adsignificantdifferenceResults:Inthisstudy,allofthe218patients,1,2,3yearsurvivalrateswere61.5%,22.9%,11.9%,themediansurvivaltimeWas14.5months,152casesofpatients、Ⅳitlllimitedstage,66casesofpatients谢t11extensivestage.Inlimitedstage,1,2,3yearsurvivalrateswere70.4
6、%,27%,14.5%,,themediansurvivaltimeWas16.8months,inextensivestage,1,23yearsurvivalrateswere40.9%,13.6%,6.1%,themediansurvivaltimeWas8.8months,P<0.001,therearesignificantdifferences.KPSscore≥80patientsfor1year,2year,3yearsurvivalrateswere66.9%,27.5%,12.5%,KPS<80
7、patientsforlyear,2year,3yearsurvivalrateswere46.6%,10.3%,10.3%,P8、therearesignificant3大连医科大学硕士学位论文differences.First-linechemotherapycyclecount<4cycleswerel,2,3yearsurvivalrateswere41.1%,16.1%,7.1%,first—linechemotherapycyclecount≥4cycleswere1,2,3
8、therearesignificant3大连医科大学硕士学位论文differences.First-linechemotherapycyclecount<4cycleswerel,2,3yearsurvivalrateswere41.1%,16.1%,7.1%,first—linechemotherapycyclecount≥4cycleswere1,2,3
此文档下载收益归作者所有